Mapping of melanin-concentrating hormone receptor 1 B cell epitopes predicts two major binding sites for vitiligo patient autoantibodies

被引:12
作者
Gavalas, Nikos G. [1 ]
Gottumukkala, Raju V. S. R. K. [1 ]
Gawkrodger, David J. [2 ]
Watson, Philip F. [1 ]
Weetman, Anthony P. [1 ]
Kemp, E. Helen [1 ]
机构
[1] Univ Sheffield, Sch Med & Biomed Sci, Sheffield S10 2JF, S Yorkshire, England
[2] Royal Hallamshire Hosp, Dept Dermatol, Sheffield S10 2JF, S Yorkshire, England
关键词
autoantibody; autoantigen; epitope; melanin-concentrating hormone receptor 1; vitiligo; MOLECULAR CHARACTERIZATION; AUTOIMMUNE-DISEASES; GRAVES-DISEASE; PHAGE DISPLAY; ANTIBODIES; PROTEIN; IDENTIFICATION; AUTOANTIGEN; IA-2; HORMONE-RECEPTOR-1;
D O I
10.1111/j.1600-0625.2008.00813.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The melanin-concentrating hormone receptor 1 (MCHR1) has been identified as a B cell autoantigen in vitiligo with antibodies to the receptor detectable in binding and function-blocking assays. Two epitope domains ( amino acids 1-138 and 139-298) have been previously identified. In this study, we aimed to further define the epitope specificity of MCHR1 antibodies using phage-display technology and to identify the epitopes recognised by receptor antibodies detected in MCHR1 function-blocking assays. Antibody reactivity to MCHR1 peptides 51-80, 85-98, 154-158 and 254-260 was identified by phagedisplay and subsequently confirmed in phage ELISA in 2/12, 5/12, 3/12 and 6/12 of vitiligo patients, respectively. The results suggest that major autoantibody epitopes are localised in the 85 98 and 254-260 amino acid regions of MCHR1 with minor epitopes in amino acid sequences 51-80 and 154-158. Antibodies with MCHR1 function-blocking activity were determined to recognise epitope 254-260, this being the first epitope to be reported as a target site for antibodies that block the function of the receptor.
引用
收藏
页码:454 / 463
页数:10
相关论文
共 36 条
[1]   CLINICAL VARIATION OF AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED) IN A SERIES OF 68 PATIENTS [J].
AHONEN, P ;
MYLLARNIEMI, S ;
SIPILA, I ;
PERHEENTUPA, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (26) :1829-1836
[2]   Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis [J].
Al-Bukhari, TAMA ;
Radford, PM ;
Bouras, G ;
Davenport, C ;
Trigwell, SM ;
Bottazzo, GF ;
Lai, M ;
Schwartz, HL ;
Tighe, PJ ;
Todd, I .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 130 (01) :131-139
[3]   Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families [J].
Alkhateeb, A ;
Fain, PR ;
Thody, A ;
Bennett, DC ;
Spritz, RA .
PIGMENT CELL RESEARCH, 2003, 16 (03) :208-214
[4]  
BARAKAT S, 1992, CLIN EXP IMMUNOL, V89, P38
[5]   ASSEMBLY OF COMBINATORIAL ANTIBODY LIBRARIES ON PHAGE SURFACES - THE GENE-III SITE [J].
BARBAS, CF ;
KANG, AS ;
LERNER, RA ;
BENKOVIC, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (18) :7978-7982
[6]   CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases [J].
Blomhoff, A ;
Helen Kemp, E ;
Gawkrodger, DJ ;
Weetman, AP ;
Husebye, ES ;
Akselsen, HE ;
Lie, BA ;
Undlien, DE .
PIGMENT CELL RESEARCH, 2005, 18 (01) :55-58
[7]   Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: Overlap of antibody and T cell determinants [J].
Dromey, JA ;
Weenink, SM ;
Peters, GH ;
Endl, J ;
Tighe, PJ ;
Todd, I ;
Christie, MR .
JOURNAL OF IMMUNOLOGY, 2004, 172 (07) :4084-4090
[8]   HLA class II haplotype DRB1*04-DQB1*0301 contributes to risk of familial generalized vitiligo and early disease onset [J].
Fain, PR ;
Babu, SR ;
Bennett, DC ;
Spritz, RA .
PIGMENT CELL RESEARCH, 2006, 19 (01) :51-57
[9]  
Farilla L, 2002, EUR J IMMUNOL, V32, P1420, DOI 10.1002/1521-4141(200205)32:5<1420::AID-IMMU1420>3.0.CO
[10]  
2-B